AngioDynamics Inc. has recently released its 10-Q report, providing a detailed insight into the company's operations and financial performance. AngioDynamics, a medical technology company, focuses on designing, manufacturing, and selling medical, surgical, and diagnostic devices for treating peripheral vascular disease, oncology, and surgical settings in the United States and internationally. The company's product portfolio includes Auryon Atherectomy system, thrombus management devices, NanoKnife IRE Ablation System, peripheral products, and more.
In the 10-Q report, AngioDynamics discussed its financial condition and results of operations. For the three months ended August 31, 2025, the company reported a 12.2% increase in revenue to $75.7 million. The Med Tech and Med Device segments experienced growth of 26.1% and 2.3%, respectively. The gross margin increased to 55.3%, with Med Tech gross margin at 62.2% and Med Device gross margin at 49.3%. The net loss decreased by $1.9 million to $10.9 million, with a decrease in loss per share by $0.05 to $0.26.
The company's net sales for the three months ended August 31, 2025, increased by $8.2 million to $75.7 million compared to the same period in the prior year. The Med Tech segment's net sales increased by $7.3 million, primarily driven by increased sales of Auryon, the thrombus management platform, and NanoKnife. The Med Device segment's net sales increased by $0.9 million, driven by growth in the Core and Venous product lines.
The gross margin for the Med Tech segment increased by $4.2 million, while the Med Device segment's gross margin increased by $0.9 million for the three months ended August 31, 2025, compared to the same period in the prior year. The total company gross margin increased by $5.1 million, primarily driven by sales volume, price, and product mix.
Additionally, the report outlined the operating expenses and other income (expense) for the same period. Research and development expenses, selling and marketing expenses, and general and administrative expenses increased slightly, attributed to factors such as compensation and benefits expenses and other operating costs.
AngioDynamics' 10-Q report offers a comprehensive overview of the company's financial performance and business operations for the period, providing valuable insights for investors and stakeholders. Today the company's shares have moved 6.05% to a price of $11.74. For the full picture, make sure to review ANGIODYNAMICS INC's 10-Q report.
